NCT06903234Active, not recruiting
Post-authorization Safety Study of Iptacopan in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Using Data From the IPIG PNH Registry
Post-authorization Safety Study of Iptacopan in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Using Data From the Non-interventional IPIG PNH Registry
Source: ClinicalTrials.gov · Last updated 23 Jun 2026
Brief summary (registry, in English)
This is an observational single-arm descriptive cohort study based on the secondary use of data collected on iptacopan-treated patients with paroxysmal nocturnal hemoglobinuria (PNH) through the International PNH Interest Group (IPIG) PNH registry.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 24 Mar 2025
- Start date
- 31 Mar 2025
- Primary completion date
- 1 Oct 2029
- Lead sponsor
- Novartis Pharmaceuticals
- NCT number
- NCT06903234
What you commit to
- Study type: Observational
- Planned participants: 200
- From 31 Mar 2025 to the primary completion date, 1 Oct 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Participation in an interventional clinical trial
Who the study is looking for
- Signed informed consent to participate in the IPIG PNH Registry
- PNH confirmed by flow cytometry
- Incident users of iptacopan
- Aged at least 18 years at the iptacopan initiation
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Basel | Switzerland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.